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TAT-Mediated Delivery of a DNA Repair Enzyme
to Skin Cells Rapidly Initiates Repair of UV-Induced
DNA Damage
Jodi L. Johnson1, Brian C. Lowell1, Olga P. Ryabinina1, R. Stephen Lloyd1,2,3 and Amanda K. McCullough1,2,3
UV light causes DNA damage in skin cells, leading to more than one million cases of non-melanoma skin cancer
diagnosed annually in the United States. Although human cells possess a mechanism (nucleotide excision
repair) to repair UV-induced DNA damage, mutagenesis still occurs when DNA is replicated before repair of
these photoproducts. Although human cells have all the enzymes necessary to complete an alternate repair
pathway, base excision repair (BER), they lack a DNA glycosylase that can initiate BER of dipyrimidine
photoproducts. Certain prokaryotes and viruses produce pyrimidine dimer-specific DNA glycosylases (pdgs)
that initiate BER of cyclobutane pyrimidine dimers (CPDs), the predominant UV-induced lesions. Such a pdg
was identified in the Chlorella virus PBCV-1 and termed Cv-pdg. The Cv-pdg protein was engineered to contain
a nuclear localization sequence (NLS) and a membrane permeabilization peptide (transcriptional transactivator,
TAT). Here, we demonstrate that the Cv-pdg-NLS-TAT protein was delivered to repair-proficient keratinocytes
and fibroblasts, and to a human skin model, where it rapidly initiated removal of CPDs. These data suggest a
potential strategy for prevention of human skin cancer.
Journal of Investigative Dermatology (2011) 131, 753–761; doi:10.1038/jid.2010.300; published online 7 October 2010
INTRODUCTION
Over one million people in the United States are diagnosed
with basal cell carcinomas (BCC) and squamous cell
carcinomas (SCC) annually, and billions of dollars are spent
in associated health care costs (Bickers et al., 2006). Exposure
to UV in sunlight results in SCC and BCC by causing DNA
damage that, if unrepaired or repaired incorrectly, can lead
to mutations in genes such as the ras oncogene or the tumor
suppressor p53 (reviewed in Hussein, 2005). The predomi-
nant DNA lesions induced by UV are cyclobutane pyrimidine
dimers (CPDs). Humans possess only one mechanism, the
nucleotide excision repair (NER) pathway, for repairing
CPDs. The importance of this single DNA repair system in
limiting SCC and BCC formation is best demonstrated by the
study of xeroderma pigmentosum patients who have muta-
tions in genes involved in the NER pathway or in a
specialized DNA polymerase that catalyzes DNA synthesis
past UV-induced DNA lesions. These patients have more
than a 1,000-fold increased risk of developing skin cancer
compared with the general population (reviewed in Kraemer
et al., 2007).
In addition to NER, other organisms utilize the base
excision repair (BER) pathway for repairing UV-induced DNA
lesions. Although humans possess a functional BER pathway
for many base lesions, they lack the initiating glycosylase
to catalyze BER in response to photo-damage of DNA. It is
hypothesized that exogenous delivery of BER-initiating repair
enzymes to UV-exposed skin cells may promote rapid,
accurate repair of CPDs, providing protection against skin
cancer. Indeed, the bacteriophage T4-pyrimidine dimer-
specific DNA glycosylase (T4-pdg), also called T4 endonu-
clease V, enhances repair of CPDs and reduces the frequency
of UV-induced mutations in cultured mammalian cells when
introduced by DNA transfection or by direct protein delivery
via encapsulation into a liposomal delivery vehicle (Kibitel
et al., 1991; Yarosh et al., 1992; Kusewitt et al., 1994, 1998;
Francis et al., 2000; Cafardi and Elmets, 2008).
Xeroderma pigmentosum patients topically treated with
liposome-encapsulated T4-pdg enzyme for 1 year exhibited a
68% decrease in new pre-cancerous actinic keratoses and a
30% decrease in new cases of BCC compared with patients
treated with placebo lotion (Yarosh et al., 2001). Repair-
proficient human populations could also potentially benefit
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from clinical trials exploring the use of pdg treatment for
prevention of skin cancer, but such studies have not yet been
published. For example, aged individuals who frequently
develop actinic keratoses, up to 10% of which convert to
SCCs (Dodson et al., 1991), and immune suppressed organ
transplant patients, who can be up to 250 times more likely
than the general public to develop aggressive, metastatic skin
cancer (Abgrall et al., 2002) could both benefit from such
studies. It is also unknown what impact pdg delivery could
have on skin cancer prevention in the general public, in
whom accumulated lifetime UV exposure and number of
sunburns lead to SCC, BCC, and melanoma (Hussein, 2005;
Dennis et al., 2008).
Although T4-pdg has been tested for efficacy to prevent skin
cancer in xeroderma pigmentosum patients, no homologues of
T4-pdg have been studied for this purpose. Chlorella virus
(Cv)-pdg, a pdg with 41% sequence identity to T4-pdg, is
expressed by a Cv that infects the eukaryotic Paramecium
bursaria chlorella algae (Furuta et al., 1997). Biochemical
characterization of the Cv-pdg enzyme showed that, in
addition to cleaving cis-syn CPDs similarly to T4-pdg, Cv-
pdg also cleaved less prevalent, but mutagenic types of UV-
induced DNA lesions including trans-syn-II CPDs (McCul-
lough et al., 1998), FapyAde and FapyGua (Jaruga et al.,
2002). Additionally, Cv-pdg is more active over a broader
range of salt concentrations and maintains activity after
exposure to more extreme temperatures than T4-pdg (McCul-
lough et al., 1998). Owing to these potential advantages over
T4-pdg for pharmaceutical use, Cv-pdg was selected for the
present study. In an effort to enhance the utility of Cv-pdg to
remove CPDs in NER-proficient human skin cells following
UV exposure, the enzyme was engineered with a nuclear
localization sequence (NLS) to enhance targeting to the
nucleus. As unaided absorption of small molecules into the
skin is limited to B500Da (Bos and Meinardi, 2000), the
B18 kDa Cv-pdg-NLS enzyme was also conjugated to a cell
membrane permeabilization sequence, TAT (transcriptional
transactivator peptide) from human immunodeficiency virus,
that is capable of transdermal delivery of conjugated peptides
up to B20kDa (Lopes et al., 2005).
In this study, we examined the delivery of Cv-pdg-NLS-
TAT enzyme to cultured repair-proficient keratinocytes and
fibroblasts and to the basal keratinocytes of a stratified human
skin model. We also examined the ability of Cv-pdg-NLS-TAT
to initiate repair of CPDs in these cells.
RESULTS
Purified pdg proteins retained activity in vitro after addition of
NLS and TAT peptides to enhance cellular delivery
As T4-pdg lacks a native NLS, the majority of T4-pdg used in
previous studies remained cytoplasmic and entered the
nucleus only through passive diffusion (Yarosh et al., 1994).
To direct T4-pdg and Cv-pdg to the nuclei of human
keratinocytes and fibroblasts to initiate repair of UV-induced
DNA damage, both pyrimidine dimer-specific DNA glycosy-
lases (pdgs) were modified to express a NLS peptide
(Pro–Lys–Lys–Arg–Lys–Arg–Arg–Leu) at the carboxy terminus.
A green fluorescent protein (GFP) tag was also added,
generating the modified T4-pdg-NLS-GFP and Cv-pdg-NLS-
GFP proteins. Following transient transfection of these plasmids
into HaCaT keratinocytes and immortalized human skin
fibroblasts, localization of these proteins was shown to be
predominantly nuclear (Figure 1a). In contrast, expression
of the unmodified T4-pdg-GFP and Cv-pdg-GFP proteins
demonstrated predominantly cytoplasmic localization. These
data provide the first evidence that engineered targeting of
these enzymes effectively increased the local concentration
in the nucleus.
In order to achieve delivery of pdg-NLS proteins to skin
cells without making use of gene transfection, the T4-pdg-
NLS and Cv-pdg-NLS genes were further engineered at the
carboxy terminus, following the NLS, to encode a peptide
known to facilitate transmembrane protein delivery (TAT –
Tyr–Gly–Arg–Lys–Lys–Arg–Arg–Gln–Arg–Arg–Arg). Following
addition of the NLS and TAT sequences and protein
expression, the resulting purified proteins (Figure 1b) were
tested for activity using a plasmid nicking assay. The engineered
pdg enzymes retained glycosylase/abasic site (AP) lyase
activity to cleave CPDs in UVC-irradiated plasmid DNA
(Figure 1c). The conversion of form I DNA (covalently closed
circular, supercoiled plasmid DNA) to forms II (nicked duplex
DNA) and III (linear duplex DNA) indicated active cleavage
of CPDs by the pdg enzymes compared with the plasmid not
treated with a pdg enzyme (). As Cv-pdg has both a broader
substrate specificity and greater enzymatic stability, the
remaining cellular experiments presented herein tested only
the engineered Cv-pdg-NLS-TAT protein.
Delivery of Cv-pdg-NLS-TAT protein to the nuclei of cultured
human skin cells and to a stratified human skin model
To determine whether the exogenously delivered B20 kDa
Cv-pdg-NLS-TAT protein could traverse skin cell membranes
and localize to the nuclei, cells were incubated with
4 mgml1 Cv-pdg-NLS-TAT protein in the medium for 4 hours
and harvested for fractionation. Immunoblots of fractionated
cell lysates revealed differences between keratinocytes
and fibroblasts with regard to enzyme delivery (Figure 2a).
Cv-pdg-NLS-TAT was detected in the nuclei of both
keratinocytes and fibroblasts by 2 hours, with higher levels
in the nuclei of the fibroblasts. As the mechanism by which
TAT mediates transduction of proteins across cellular
membranes remains controversial and may change depend-
ing on the cargo (Green et al., 2003; Richard et al., 2005), it is
unknown whether differences in cell membrane composition
or endocytosis capabilities might explain the observed
differences between keratinocytes and fibroblasts with regard
to uptake of Cv-pdg-NLS-TAT.
To determine the persistence of the enzyme in the cells
after removal of excess enzyme in the medium, cells were
incubated for 4 hours with Cv-pdg-NLS-TAT and then washed
(D) with phosphate-buffered saline (PBS). Fresh medium
without enzyme was added and whole cell lysates were
examined by immunoblot at various times after enzyme
removal. The fibroblasts maintained the protein for up to
44 hours after medium change (48 hours total incubation,
data not shown). However, the keratinocytes exhibited
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decreased levels of Cv-pdg-NLS-TAT protein by 1.5 hours
after medium change and immunoblot analyses revealed that
the protein was increasingly found in the medium (Figure 2b).
Following this observation, to rule out the possibility that
the Cv-pdg-NLS-TAT protein was influencing overall cell
membrane permeability, keratinocytes and fibroblasts were
stained with 0.4% Trypan Blue both immediately and 0.5, 1,
and 2 hours after removal of extracellular Cv-pdg-NLS-TAT.
The number of cells that stained with Trypan Blue (o2%) did
not change in the presence of Cv-pdg-NLS-TAT in either cell
type (data not shown), suggesting that overall changes in
membrane permeability were not the reason for the reduction
of Cv-pdg-NLS-TAT in the keratinocytes and its appearance
in the medium.
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Figure 1. Purified pdg proteins retain activity in vitro after addition of NLS and TAT peptides to enhance cellular delivery. (a) Human keratinocytes and
skin fibroblasts were transfected with expression vectors for GFP, pdg-GFP, or pdg-NLS-GFP and GFP localization was visualized by direct immunofluoresence
microscopy. DAPI (blue) indicates nuclei. Scale bar¼10 mm. (b) Coomassie blue–stained 15% SDS-PAGE gel showing the purity of pdg, pdg-NLS, or pdg-NLS-
TAT enzymes after protein expression and purification. (c) Plasmid nicking assay on UVC-irradiated DNA showing in vitro activity of the purified pdg enzymes
after addition of NLS and TAT peptides. I¼ covalently closed circular, supercoiled plasmid DNA; II¼nicked duplex DNA; III¼ linear duplex DNA;
()¼plasmid not treated with a pdg. Cv, Chlorella virus; DAPI, 40,6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein;
GFP, green fluorescent protein; NLS, nuclear localization sequence; pdg, pyrimidine dimer-specific DNA glycosylase; TAT, transcriptional transactivator peptide.
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The Cv-pdg-NLS-TAT enzyme must be delivered through
the stratum corneum of intact skin in order to catalyze DNA
repair in basal keratinocytes from which a majority of
non-melanoma skin cancers arise. To determine whether
the Cv-pdg-NLS-TAT protein could traverse the stratum
corneum, the enzyme was applied to the surface of a human
skin model (Mattek Epiderm-FT, Mattek, Ashland, MA). This
model is composed of dermal fibroblasts and stratified
epidermal layers including basal keratinocytes, differentiated
keratinocytes, and a stratum corneum. Cv-pdg-NLS-TAT was
successfully delivered to the skin model as determined by
immunoblot of whole tissue cellular lysates (Figure 2c). To
test persistence of Cv-pdg-NLS-TAT in the skin, the enzyme
was washed from the skin model surface with PBS after
4 hours of incubation (D), and remained detectable by
immunoblot up to 20 hours after washing (24 hours total
incubation).
To determine whether the Cv-pdg-NLS-TAT protein was
delivered to basal keratinocytes in addition to differentiated
keratinocytes, skin model samples that were incubated for
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Figure 2. Delivery of Cv-pdg-NLS-TAT protein to the nuclei of cultured human skin cells and to a stratified human skin model. (a) Immunoblot of cytoplasmic
(C) and nuclear (N) lysates after incubation with buffer (B) or Cv-pdg-NLS-TAT. Histone H3 and a-tubulin mark nuclei and cytoplasm, respectively.
(þ )¼ purified Cv-pdg-NLS-TAT. (b) Immunoblot of Cv-pdg-NLS-TAT in concentrated medium or whole keratinocyte lysates. (c) Immunoblot of lysates from skin
model tissues treated with buffer (B) or Cv-pdg-NLS-TAT. (d) Upper left: H&E staining of the skin model; lower left: IIF for expression of K14 (red) and loricrin
(green) with DAPI (blue) for nuclei; right: IIF of Cv-pdg (red) after culturing with buffer (upper) or Cv-pdg-NLS-TAT (lower). Solid bar¼50 mm. Dashed
bar¼ 20 mm. Cv, Chlorella virus; DAPI, 40,6-diamidino-2-phenylindole; H&E, hematoxylin–eosin; IIF, indirect immunofluorescence; NLS, nuclear localization
sequence; pdg, pyrimidine dimer-specific DNA glycosylase; TAT, transcriptional transactivator peptide.
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2 hours with buffer or Cv-pdg-NLS-TAT were analyzed by
indirect immunofluorescence (IIF) using the Cv-pdg antibody.
The upper left panel of Figure 2d shows hematoxylin–eosin
staining of the skin model and the lower left panel shows
expression of specific epidermal markers, keratin 14 and
loricrin, to demarcate basal keratinocytes and more differ-
entiated keratinocytes, respectively. The upper right panel
shows background fluorescence of the skin model incubated
with buffer, whereas the lower right panel demonstrates that
Cv-pdg-NLS-TAT was localized throughout the stratified
epidermis, including the basal keratinocytes. Although Cv-
pdg-NLS-TAT was nuclear in some of the basal keratinocytes
and almost all of the dermal fibroblasts, the enzyme
surprisingly was primarily cytoplasmic in many basal and
differentiated keratinocytes. This observation cannot be
explained by loss of the NLS-TAT peptides since the protein
size was not altered upon delivery to the skin (comparing
sizes of pdgs with and without the NLS and TAT peptides in
Figures 2c and 1b). Rather, the observation may be consistent
with data from cultured keratinocytes that exhibited less Cv-
pdg-NLS-TAT uptake and reduced retention of the enzyme
compared with fibroblasts (Figure 2a and b).
Cv-pdg-NLS-TAT catalyzed rapid CPD cleavage in
UVB-exposed skin cells
Although the Cv-pdg-NLS-TAT protein retained activity
in vitro as purified from E. coli, it was not known whether
the enzyme would remain active to cleave CPDs once it had
crossed the stratum corneum and the cellular and nuclear
membranes of human skin cells. To address this question,
cells plated on microscope cover slips were incubated with
buffer or 2 mg of Cv-pdg-NLS-TAT per ml of culture medium
for 4 hours before exposure to 100 Jm2 UVB. After exposure,
medium containing Cv-pdg-NLS-TAT or buffer was refreshed
so that the cells were incubated in the continual presence of
the enzyme. The cells were fixed immediately after UVB
exposure or 24 hours later and stained for detection of intact
CPDs by IIF microscopy. Owing to their normal NER
proficiency, the buffer-treated keratinocytes exhibited a
decrease in CPD detection by 24 hours (Figure 3a left series
of panels). In striking contrast, the CPDs were nearly
undetectable by IIF in Cv-pdg-NLS-TAT-treated keratinocytes
as rapidly as the cells could be harvested after UVB exposure
(Figure 3a right series of panels). Similar results were obtained
for the NER-proficient fibroblasts (data not shown).
To further characterize the ability of Cv-pdg-NLS-TAT to
initiate repair of CPDs in UVB-exposed skin cells, cells were
pre-incubated for 4 hours with buffer or varying concentra-
tions of Cv-pdg-NLS-TAT, exposed to 300 Jm2 UVB,
allowed to recover for 4 hours in the continual presence of
buffer or enzyme, and then fixed and analyzed by IIF to
detect CPD presence using an automated imager. As shown
in the left graph of Figure 3b, keratinocytes treated with 1 or
2 mg of Cv-pdg-NLS-TAT per ml of medium exhibited reduced
CPD levels compared with cells treated with buffer alone.
The detection of CPDs was reduced in fibroblasts treated with
as little as 63 ng Cv-pdg-NLS-TAT per ml of medium
compared with cells incubated with only buffer (right graph
of Figure 3b), consistent with the data showing increased
cellular uptake of Cv-pdg-NLS-TAT in fibroblasts (Figure 2a).
For comparison, it is noted that a concentration of 1 mg of T4-
pdgml1 was used in several previously published studies
making use of that enzyme (Yarosh et al., 2001; Hacker et al.,
2010).
To determine whether the UVB dose impacted the ability
of CV-pdg-NLS-TAT to initiate CPD repair, cells were either
incubated with buffer before and after exposure to increasing
UVB doses (black bars Figure 3c), pre-incubated for 4 hours
with 1 mgml1 Cv-pdg-NLS-TAT followed by addition of fresh
1 mgml1 Cv-pdg-NLS-TAT immediately after UVB exposure
(dark grey bars Figure 3c), or incubated with buffer for 4 hours
before UVB exposure followed by addition of 1 mgml1 Cv-
pdg-NLS-TAT immediately after UVB exposure (light grey
bars Figure 3c). Cells were fixed 4 hours after UVB exposure
and analyzed by automated microscopy for IIF indicating
CPD presence. Incubation with CV-pdg-NLS-TAT reduced
the detectable CPDs in both keratinocytes and fibroblasts
exposed to up to 400 Jm2 UVB compared with cells
incubated with buffer alone. At the 300 and 400 Jm2 UVB
exposures, Cv-pdg-NLS-TAT incubation pre- and post-expo-
sure led to fewer detectable CPDs compared with cells that
were given Cv-pdg-NLS-TAT only after UVB exposure. The
difference between these two conditions was more subtle in
the fibroblasts than in the keratinocytes, again possibly
correlating with the more efficient enzyme uptake and
retention observed in the fibroblasts (Figure 2a).
Next, experiments were conducted to determine whether
Cv-pdg-NLS-TAT was capable of cleaving CPDs in the UVB-
exposed skin model. The tissues were incubated for 4 hours
with buffer or 3 mg Cv-pdg-NLS-TAT. After washing the
enzyme from the skin model surface with PBS (D), the tissues
were exposed to no UVB or 500 Jm2 UVB (a higher dose
than for cultured cells because UVB must penetrate through
the layers of the skin model) followed by 4 hours of recovery.
IIF microscopy using the CPD antibody revealed reduced
CPD fluorescence in the UVB-exposed cells of the skin model
that had been pre-treated with Cv-pdg-NLS-TAT compared
with those incubated with buffer (Figure 3d). Although Cv-
pdg-NLS-TAT appeared to localize in the cytoplasm of many
basal and differentiated keratinocytes (Figure 2d lower right
panel), the reduced CPD levels presented in Figure 3d
demonstrate that nuclear levels of the enzyme were sufficient
to induce rapid cleavage of CPDs following UVB exposure in
the majority of skin cells.
DISCUSSION
The aim of this study was to demonstrate the feasibility of
delivering an active DNA repair enzyme, Cv-pdg, to NER-
proficient human keratinocytes and fibroblasts to initiate
BER of UV-induced DNA damage. The data demonstrate that
by engineering Cv-pdg to be expressed as a fusion with NLS
and TAT peptides, such a modified enzyme can be delivered
to the nuclei of cultured human keratinocytes and fibroblasts,
as well as across the stratum corneum to the basal
keratinocytes of a stratified human skin model. This
Cv-pdg-NLS-TAT enzyme significantly increased the rate of
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initiation of CPD repair in NER-proficient skin cells following
UVB exposure.
To our knowledge, TAT-mediated delivery of an active
DNA repair enzyme across the barrier of a human skin
model has previously not been reported, though other
studies show TAT-mediated delivery of other enzymes and
peptides to mouse and porcine skin (Lopes et al., 2005;
Nakashima-Kamimura et al., 2008; Song et al., 2008).
Although the current study made use of a cultured model of
human skin, the stratum corneum and thickness of the
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Figure 3. Cv-pdg-NLS-TAT catalyzed rapid CPD cleavage in UVB-exposed skin cells. (a) IIF to detect CPDs (green) in UVB-exposed keratinocytes pre-incubated
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epidermal layers are highly similar to those found in vivo and
it is thought that the use of such models represents a valid
way to initially test epidermal drug delivery (Zghoul et al.,
2001). Our data demonstrate that Cv-pdg-NLS-TAT delivery
to a skin model is feasible, thus advancing a method for
delivering therapeutic proteins across the skin barrier without
the need for encapsulation into a delivery vehicle.
The data suggest differences between keratinocytes and
skin fibroblasts with regard to the efficiency of TAT-mediated
enzyme uptake, warranting further study. It is possible that
the Cv-pdg-NLS-TAT sequence or delivery conditions can
be further optimized to enhance uptake and retention of the
enzyme, particularly in basal keratinocytes. As these keratino-
cytes divide to replenish the upper cell layers and have been
shown to be able to proliferate in the presence of potentially
mutagenic CPDs (Courdavault et al., 2005), these cells are
perhaps the most critical targets for Cv-pdg-NLS-TAT activity
towards skin cancer prevention. Further, the persistence of
CPDs in a particular subset of UV-irradiated basal keratino-
cytes is thought to be a key component of cellular transforma-
tion during skin carcinogenesis (Mitchell et al., 2001).
Although normal human skin cells are capable of repairing
UV-induced DNA damage through the NER pathway, the
kinetics of CPD repair are relatively slow (Mouret et al.,
2008). Interestingly, the most frequently formed CPDs,
thymine–thymine dimers, are especially poorly recognized
by NER machinery. In the Mouret et al. study,B40 and 50%
of these lesions remained in the DNA of cultured primary
human keratinocytes and fibroblasts, respectively, 48 hours
after exposure to 200 Jm2 UVB. In skin biopsies exposed to
1,000 Jm2 UVB, the kinetics of repair of thymine–thymine
dimers were even slower withB60% of lesions remaining in
the genome after 48 hours. It was shown that enhancing the
rate of CPD repair using the CPD-photolyase enzyme (Jans
et al., 2005) or T4-pdg (Yarosh et al., 1992; Bito et al., 1995),
reduced the incidence of non-melanoma skin tumors in
NER-proficient mice. In the current study, Cv-pdg-NLS-TAT,
a DNA repair enzyme with broader substrate specificity than
the previously studied T4-pdg (Jaruga et al., 2002; McCullough
et al., 1998), was delivered to NER-proficient human skin cells
and rapidly initiated CPD repair.
Cv-pdg-NLS-TAT may be a useful agent for prevention of
skin cancer in NER-deficient xeroderma pigmentosum
patients, as well as specific NER-proficient populations, such
as aged individuals and immunosuppressed organ transplant
patients. Increased age correlates with a decreased rate
of CPD repair following UV exposure, likely contributing to
the exponentially increasing incidence of skin cancer
associated with advancing age (Goukassian et al., 2000).
Immune suppressed organ transplant patients frequently
develop aggressive, metastatic SCCs (Abgrall et al., 2002).
Regular sunscreen use decreases the skin cancer incidence in
transplant patients, suggesting that reducing UV-induced
DNA damage could lead to skin cancer prevention in
this population (Ulrich et al., 2009). In conjunction with
sunscreen use and sun protective behaviour, Cv-pdg-
NLS-TAT treatment could be recommended to patients taking
immunosuppressive drugs and aged patients to increase
the cellular capacity to initiate CPD repair to prevent
skin cancer.
Cv-pdg-NLS-TAT may also be useful for the prevention of
SCC, BCC, and even melanoma in the general public. The
total number of sunburns experienced throughout life and,
specifically, DNA lesions in the form of CPDs have a role in
melanoma etiology (Mitchell et al., 2007; Dennis et al., 2008;
Wang et al., 2009). It should be noted that treatment with
T4-pdg (lacking a NLS) before neonatal UV exposure of a
melanoma-prone mouse model yielded no effect on the
incidence or age of onset of melanoma compared with
placebo treated controls, even though the enzyme initiates
rapid repair of CPDs in the skin of the treated mice (Hacker
et al., 2010). However, Cv-pdg-NLS-TAT could be more
useful for melanoma prevention than T4-pdg because of its
broader substrate specificity and the inclusion of the NLS to
improve nuclear concentration. Cv-pdg-NLS-TAT will need
to be tested for safety before efficacy trials can be conducted
for prevention of skin cancer in humans. Although humans
treated with T4-pdg showed no adverse effects or changes in
skin histology (Yarosh et al., 1996), Cv-pdg and T4-pdg share
only 41% homology and it is unknown whether Cv-pdg
protein or the NLS or TAT peptides will produce an allergic
response or other negative effects in humans.
In conclusion, we showed that delivery of Cv-pdg-NLS-
TAT to human skin cells leads to rapid initiation of CPD
repair following exposure to UVB. Future studies will
investigate the subsequent enzymatic steps and the biological
consequences following initiation of CPD repair by Cv-pdg-
NLS-TAT in repair-proficient human skin cells.
MATERIALS AND METHODS
Cell and skin model culture, and UVB exposure
Spontaneously immortalized, NER-proficient human HaCaT keratino-
cytes (Boukamp et al., 1988; Takasawa et al., 2005) and an E6/E7
immortalized human skin fibroblast line (Iordanov et al., 2000) from
a healthy donor were grown in high glucose DMEM supplemented
with 10% heat-inactivated fetal bovine serum (Hyclone, Thermo
Fisher Scientific, South Logan, UT) and 1% antibiotics/antimycotics
(Invitrogen, Carlsbad, CA). The Mattek Epiderm FT human skin
model (Mattek) was cultured as suggested by the manufacturer for
48 hours before experiments. For UVB experiments, cells (in
sufficient PBS to minimally cover the culture plate surface) or tissues
were irradiated under a F15T8 UVB bulb with peak irradiance at
302 nm wavelength in a Blak-Ray XX-15M UV Bench Lamp
(Ultraviolet Products, Upland, CA). The exposure time (seconds)
required to obtain the UVB doses (Jm2) used throughout this
study was calculated by measuring mWcm2 using an IL1400A
photometer (International Light Technologies, Peabody, MA) calib-
rated annually by the manufacturer. The samples were exposed for
15 seconds for each 100 Jm2 UVB at a distance of 14 cm from the
light source.
Expression vectors and enzyme purification
For cell transfection to demonstrate nuclear localization of pdg
enzymes following addition of an NLS, the T4-pdg, T4-pdg-NLS,
Cv-pdg, or Cv-pdg-NLS genes were subcloned into the pEGFP-N3
vector (Clontech, Mountain View, CA). For pdg enzyme purification,
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the above genes were subcloned into the pET-22b(þ ) vector with
a carboxy-terminal 6 histidine tag (Novagen, EMD chemicals,
Gibbstown, NJ). Standard purification protocols using Ni-NTA
agarose beads were used to purify these enzymes to apparent
homogeneity. The Supplementary Text online details methods for
pdg protein purification.
Transfection and visualization
HaCaT keratinocytes and immortalized human fibroblasts were
cultured to 60% confluence on microscope cover slips (Fisher
Scientific, Houston, TX) in a 6-well tissue culture dish, transiently
transfected with the appropriate pEGFP-N3 or pdg-pEGFP-N3 vector
with Lipofectin Reagent (Invitrogen), and grown for 16 hours. Cells
were fixed in 4% formalin solution for 30minutes at room
temperature and washed three times in PBS. Cover slips were
mounted on slides using ProLong Gold antifade reagent with 40,
6-diamidino-2-phenylindole (Invitrogen). Cells were visualized for
direct GFP fluorescence with a Leica DM IRB microscope under a
63 magnification objective lens.
In vitro pdg activity assay
To determine if the pdg-NLS and pdg-NLS-TAT proteins were active
to cleave DNA containing CPDs, pBR322 (Fermentas, Glen Bernie,
MD) plasmid DNA was irradiated with UVC to induce more than 25
CPDs per plasmid using a Spectroline ENF-280C lamp (Spectronics
Corporation, Westbury, NY) at 254 nm wavelength (peak intensity of
1290mWcm2 at 15.25 cm) and incubated with each purified pdg
protein at 37 1C for 1 hour in reaction buffer (25mM Tris-HCl
(pH 8.0), 20mM NaCl, 1mM EDTA, 100mgml1 BSA). Supercoiled,
nicked, and linearized DNA products were separated by electro-
phoresis through a 1% agarose gel.
Preparation of Cv-pdg-NLS-TAT for delivery to human skin cells
Purified Cv-pdg-NLS-TAT protein in elution buffer containing
400mM imidazole (see Supplementary Text online for protein
purification methods) was concentrated by centrifugation using an
Amicon device with a low-binding Ultracel membrane that has a
3 kDa molecular weight cutoff (Fisher Scientific, Houston, TX). PBS
was added and the centrifugation was repeated five times to dilute
the imidazole concentration to o20mM. A control buffer for cell
culture experiments was prepared by treating elution buffer alone
with five additions of PBS. The amount of Cv-pdg-NLS-TAT protein
delivered in these studies was as follows: 4mgml1 culture medium
for cells harvested for immunoblots to show protein delivery (Figure
2a and b); 2mgml1 culture medium for cells grown on cover slips
for IIF microscopy of CPDs (Figure 3a); the concentrations indicated
in Figures 3b and c for automated IIF microscopy of CPDs; and a
total of 3 mg topically delivered in 100 ml of PBS to each human skin
model sample (Figures 2c, d, and 3d).
Primary antibodies used for immunoblot and IIF
Primary antibodies included Cv-pdg (produced in rabbits against the
full-length non-denatured protein), a-tubulin (Sigma-Aldrich, Saint
Louis, MO), histone H3 (Active Motif, Carlsbad, CA), anti-cytokeratin
14 (Fitzgerald, Concord, MA), anti-loricrin (Covance, Emeryville, CA),
and CPD (Cosmo Bio, Tokyo, Japan using a protocol as described in
Schul et al. (2002)). Detailed methods describing preparation of
samples as well as immunoblot analyses of Cv-pdg-NLS-TAT delivery,
IIF microscopy for proteins and for CPDs, and histology of the skin
model can be found in the Supplementary Text online.
Automated imaging for detection of CPDs
Cells were cultured until B70% confluence in 24-well plates
(Corning, Corning, NY) and incubated for 4 hours with buffer or
Cv-pdg-NLS-TAT. Following UVB exposure, cells from each 24-well
sample were trypsinized and plated into 4 wells of a non-siliconized
type I collagen-coated 96-well view plate (Greiner Bio-One,
Monroe, NC). The replating step was necessary because of the
UV-protective shadowing effect of the wells in a 96-well plate.
The detection of CPDs by IIF was as detailed in Schul et al. (2002).
The Alexa Fluor 647-conjugated secondary goat anti-mouse IgG
antibody (Invitrogen) was used. Total nuclear DNA was stained
using 5mgml1 of 40, 6-diamidino-2-phenylindole (KPL, Gaithersburg,
MD). Cells were imaged with 405 and 647nm lasers using a 10
objective on an OPERA LX reader (Perkin-Elmer, Waltham, MA) at the
Oregon Translation Research and Drug Development Institute (OTRADI)
(Portland, OR). Images were analyzed using a script developed under
the Acapella software environment (Perkin–Elmer). Briefly, the nuclei
of individual cells were identified based on the 40,6-diamidino-2-
phenylindole fluorescence (read at 405nm), then the areas in the
correlating 647nm (CPD antibody stain) image were mapped and
the pixel intensities recorded on a cell-by-cell basis. More than
5,000 cells were analyzed for each sample and the mean nuclear
647nm fluorescence intensity was graphically reported.
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